Institut für Biochemie, Christian-Albrechts-Universität zu Kiel, Olshausenstrasse 40, D-24098 Kiel, Germany.
German Center for Neurodegenerative Diseases (DZNE), and Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Strasse 17, D-81377 München, Germany; Neuroproteomics, Klinikum rechts der Isar, and Institute for Advanced Study, Technische Universität München, 81675 Munich, Germany.
Prog Neurobiol. 2015 Dec;135:1-20. doi: 10.1016/j.pneurobio.2015.10.003. Epub 2015 Oct 29.
Proteins belonging to the 'A Disintegrin And Metalloproteinase' (ADAM) family are membrane-anchored proteases that are able to cleave the extracellular domains of several membrane-bound proteins in a process known as 'ectodomain shedding'. In the central nervous system, ADAM10 has attracted the most attention, since it was described as the amyloid precursor protein α-secretase over ten years ago. Despite the excitement over the potential of ADAM10 as a novel drug target in Alzheimer disease, the physiological functions of ADAM10 in the brain are not yet well understood. This is largely because of the embryonic lethality of ADAM10-deficient mice, which results from the loss of cleavage and signaling of the Notch receptor, another ADAM10 substrate. However, the recent generation of conditional ADAM10-deficient mice and the identification of further ADAM10 substrates in the brain has revealed surprisingly numerous and fundamental functions of ADAM10 in the development of the embryonic brain and also in the homeostasis of adult neuronal networks. Mechanistically, ADAM10 controls these functions by utilizing unique postsynaptic substrates in the central nervous system, in particular synaptic cell adhesion molecules, such as neuroligin-1, N-cadherin, NCAM, Ephrin A2 and A5. Consequently, a dysregulation of ADAM10 activity is linked to psychiatric and neurological diseases, such as epilepsy, fragile X syndrome and Huntington disease. This review highlights the recent progress in understanding the substrates and function as well as the regulation and cell biology of ADAM10 in the central nervous system and discusses the value of ADAM10 as a drug target in brain diseases.
属于“解整合素和金属蛋白酶”(ADAM)家族的蛋白质是膜锚定的蛋白酶,能够在称为“外域脱落”的过程中切割几种膜结合蛋白的细胞外结构域。在中枢神经系统中,ADAM10 引起了最多的关注,因为十多年前它被描述为淀粉样前体蛋白 α-分泌酶。尽管 ADAM10 作为阿尔茨海默病新型药物靶点的潜力令人兴奋,但 ADAM10 在大脑中的生理功能尚未得到很好的理解。这在很大程度上是由于 ADAM10 缺陷型小鼠的胚胎致死性,这是由于 Notch 受体的切割和信号转导丧失引起的,Notch 受体是 ADAM10 的另一种底物。然而,最近产生的条件性 ADAM10 缺陷型小鼠和大脑中进一步 ADAM10 底物的鉴定揭示了 ADAM10 在胚胎大脑发育以及成年神经元网络的动态平衡中具有惊人的众多和基本功能。从机制上讲,ADAM10 通过利用中枢神经系统中独特的突触后底物来控制这些功能,特别是突触细胞粘附分子,如神经连接蛋白-1、N-钙粘蛋白、NCAM、Ephrin A2 和 A5。因此,ADAM10 活性的失调与精神和神经疾病有关,如癫痫、脆性 X 综合征和亨廷顿病。这篇综述强调了近年来在理解 ADAM10 在中枢神经系统中的底物和功能以及调控和细胞生物学方面的进展,并讨论了 ADAM10 作为大脑疾病药物靶点的价值。